Glymipril-MV 2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (2 mg), Metformin (500 mg), and Voglibose (0.2 mg) designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose production, contributing to better glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The extended-release formulation ensures a sustained and gradual release of active ingredients, promoting consistent plasma concentrations and improving patient compliance through once-daily dosing. Glymipril-MV 2 Tablet ER is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It should be used with caution in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. This combination therapy offers a multifaceted approach to glycemic management, addressing fasting and postprandial glucose levels effectively.